Synapse - Kim Kramer

Results (23)

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission

Journal Article

Kushner, B. H.; Modak, S.; Mauguen, A.; Basu, E. M.; Kramer, K.; Roberts, S. S.; Cheung, I. Y.; Cheung, N. K. V.
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Ovarian function in female survivors of high-risk neuroblastoma

Journal Article

Jimenez-Kurlander, L.; DeRosa, A.; Kostrzewa, C. E.; Moskowitz, C. S.; Bogardus, K.; Antal, Z.; Wolden, S.; La Quaglia, M. P.; Basu, E. M.; Cardenas, F. I.; more...
Pediatric Blood and Cancer (2024)

Fulltext@MSK | Save

Phase I trial of oral yeast-derived β-glucan to enhance anti-GD2 immunotherapy of resistant high-risk neuroblastoma

Journal Article

Iglesias Cardenas, F.; Mauguen, A.; Cheung, I. Y.; Kramer, K.; Kushner, B. H.; Ragupathi, G.; Cheung, N. K. V.; Modak, S.
Cancers (2021)

Fulltext@MSK | Save

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

Journal Article

Modak, S.; Le Luduec, J. B.; Cheung, I. Y.; Goldman, D. A.; Ostrovnaya, I.; Doubrovina, E.; Basu, E.; Kushner, B. H.; Kramer, K.; Roberts, S. S.; more...
OncoImmunology (2018)

Fulltext@MSK | Save

MYCN-amplified stage 2/3 neuroblastoma: Excellent survival in the era of anti-G(D2) immunotherapy

Journal Article

Kushner, B. H.; LaQuaglia, M. P.; Modak, S.; Wolden, S. L.; Basu, E. M.; Roberts, S. S.; Kramer, K.; Yataghene, K.; Cheung, I. Y.; Cheung, N. V.
Oncotarget (2017)

Fulltext@MSK | Save

Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT)

Meeting Abstract

Kushner, B. H.; Modak, S.; LaQuaglia, M. P.; Wolden, S. L.; Basu, E. M.; Roberts, S. S.; Kramer, K.; Cheung, I. Y.; Cheung, N. K. V.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Germline mutations in cancer predisposition genes in a subset of pediatric oncology patients undergoing targeted solid tumor sequencing using matched normal DNA

Meeting Abstract

Walsh, M.; Shukla, N.; Joseph, V.; Kentsis, A.; Curran, K.; Kobos, R.; Arnold, A.; Harlan, M.; Kennedy, J.; Schrader, K.; more...
Pediatric Blood and Cancer (2016)

Fulltext@MSK | Save

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

Journal Article

Kushner, B. H.; Ostrovnaya, I.; Cheung, I. Y.; Kuk, D.; Modak, S.; Kramer, K.; Roberts, S. S.; Basu, E. M.; Yataghene, K.; Cheung, N. K. V.
Oncotarget (2016)

Fulltext@MSK | Save

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: A prospective phase II study

Journal Article

Kushner, B. H.; Ostrovnaya, I.; Cheung, I. Y.; Kuk, D.; Kramer, K.; Modak, S.; Yataghene, K.; Cheung, N. K. V.
OncoImmunology (2015)

Fulltext@MSK | Save

Osteochondroma in long-term survivors of high-risk neuroblastoma

Journal Article

Kushner, B. H.; Roberts, S. S.; Friedman, D. N.; Kuk, D.; Ostrovnaya, I.; Modak, S.; Kramer, K.; Basu, E. M.; Cheung, N. K. V.
Cancer (2015)

Fulltext@MSK | Save